Phase II trial of vorinostat with idarubicin and cytarabine for patients with newly diagnosed acute myelogenous leukemia or myelodysplastic syndrome.

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Journal of Clinical Oncology

• Publication date

  2012-06-20

• Fields of study

  Medicine

• Identifiers
  DOI 10.1200/JCO.2011.38.3265PMID 22585696PMCID PMC4879705
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Integrative prognostic risk score in acute myeloid leukemia with normal karyotype.

  2011cited by this paper
• HDACs link the DNA damage response, processing of double-strand breaks and autophagy

  2011cited by this paper
• A phase 1‐2 study of a farnesyltransferase inhibitor, tipifarnib, combined with idarubicin and cytarabine for patients with newly diagnosed acute myeloid leukemia and high‐risk myelodysplastic syndrome

  2011cited by this paper
• Overcoming resistance to histone deacetylase inhibitors in human leukemia with the redox modulating compound β-phenylethyl isothiocyanate.

  2010cited by this paper
• DNA damage-mediated induction of a chemoresistant niche.

  2010cited by this paper
• Phase II study of clofarabine monotherapy in previously untreated older adults with acute myeloid leukemia and unfavorable prognostic factors.

  2010cited by this paper
• A phase I study of vorinostat in combination with idarubicin in relapsed or refractory leukaemia

  2010influential reference
• Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia.

  2010cited by this paper
• The Combination of a Histone Deacetylase Inhibitor with the Bcl-2 Homology Domain-3 Mimetic GX15-070 Has Synergistic Antileukemia Activity by Activating Both Apoptosis and Autophagy

  2010cited by this paper
• Anthracycline dose intensification in acute myeloid leukemia.

  2009influential reference
• The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes.

  2009cited by this paper
• Anthracycline dose intensification in acute myeloid leukemia.

  2009cited by this paper
• Preclinical Studies of Vorinostat (Suberoylanilide Hydroxamic Acid) Combined with Cytosine Arabinoside and Etoposide for Treatment of Acute Leukemias

  2009cited by this paper
• Autophagy fights disease through cellular self-digestion

  2008cited by this paper
• Clinical Trials and Observations

  2008cited by this paper
• Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes.

  2008cited by this paper
• Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome.

  2007cited by this paper
• Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL).

  2007cited by this paper
• Antileukemia activity of the combination of an anthracycline with a histone deacetylase inhibitor.

  2006cited by this paper
• Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype.

  2005cited by this paper
• Apoptotic and autophagic cell death induced by histone deacetylase inhibitors

  2004cited by this paper
• Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study.

  2000cited by this paper
• International scoring system for evaluating prognosis in myelodysplastic syndromes.

  1997cited by this paper

• A Comprehensive Guide on Epigenetics' Precision Role in Uncommon "Rare" Cancers' Biology and Treatment Frontiers.

  2026cites this paper
• Current scenario of allogeneic hematopoietic stem cell transplantation in adult patients with relapsed/refractory acute myeloid leukemia: a narrative review

  2025cites this paper
• New potent N‐hydroxycinnamamide‐based histone deacetylase inhibitors suppress proliferation and trigger apoptosis in THP‐1 leukaemia cells

  2025cites this paper
• Characterizing SSTR2 expression and modulation for targeted imaging and therapy in preclinical models of triple-negative breast cancer

  2025cites this paper
• Dose-dependent dual effects of HDAC inhibitors on glial inflammatory response

  2025cites this paper
• Targeted therapy in KMT2Ar AML.

  2025cites this paper
• Histone deacetylase inhibitors: targeting epigenetic regulation in the treatment of acute leukemia

  2024cites this paper
• Tackling triple negative breast cancer with HDAC inhibitors: 6 is the isoform!

  2024cites this paper
• DUALISTIC SAHA DOSE-DEPENDENT EFFECTS ON GLIAL-INFLAMMATORY RESPONSE

  2024cites this paper
• Risk Factor for Rash in Patients Receiving Cytarabine and Idarubicin Induction Therapy for Acute Myeloid Leukemia

  2024cites this paper
• Iron overload induces dysplastic erythropoiesis and features of myelodysplasia in Nrf2-deficient mice

  2023cites this paper
• Epigenetic reprogramming in cancer: From diagnosis to treatment

  2023cites this paper
• HDAC inhibitors: Promising agents for leukemia treatment.

  2023cites this paper
• A randomized phase III study of standard versus high-dose cytarabine with or without vorinostat for AML

  2023cites this paper
• Identification of differentially expressed genes induced by aberrant methylation in acute myeloid leukemia using integrated bioinformatics analyses

  2022cites this paper
• Construction of three‐gene‐based prognostic signature and analysis of immune cells infiltration in children and young adults with B‐acute lymphoblastic leukemia

  2022cites this paper
• Vorinostat combined with Busulfan, Fludarabine, and Clofarabine Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Leukemia: Long-term Study Outcomes.

  2022cites this paper
• Functional Drug Screening of Small Molecule Inhibitors of Epigenetic Modifiers in Refractory AML Patients

  2022cites this paper
• Small molecule inhibitors targeting the cancers

  2022cites this paper
• The Role of epigenetic modifications of DNA and histones in the treatment of oncohematological diseases

  2021cites this paper
• Mitochondrial metabolism as a target for acute myeloid leukemia treatment

  2021cites this paper
• Recent Clinical Update of Acute Myeloid Leukemia: Focus on Epigenetic Therapies

  2021cites this paper
• Molecular Targeted Therapy in Myelodysplastic Syndromes: New Options for Tailored Treatments

  2021cites this paper
• A phase 1 trial of the histone deacetylase inhibitor AR-42 in patients with neurofibromatosis type 2-associated tumors and advanced solid malignancies

  2021cites this paper
• Epigenetics in acute myeloid leukemia

  2021cites this paper
• Combining Histone Deacetylase Inhibitors with Other Anticancer Agents as a Novel Strategy for Circumventing Limited Therapeutic Efficacy and Mitigating Toxicity

  2020cites this paper
• Pediatric acute myeloid leukemias treatment: current scientific view

  2020cites this paper
• Current and emerging molecular and epigenetic disease entities in acute myeloid leukemia and a critical assessment of their therapeutic modalities.

  2020cites this paper
• Histone Deacetylase Inhibitors in Combinatorial Anticancer Therapy

  2020influential citation
• HDAC inhibitors in cancer therapy

  2020cites this paper
• Possibilities of epigenetic therapy of acute myeloid leukemias in children

  2020cites this paper
• Identification of hub genes and its correlation with the prognosis of acute myeloid leukemia based on high‐throughput data analysis

  2020cites this paper
• Conditional Generative Adversarial Networks for Individualized Treatment Effect Estimation and Treatment Selection

  2020cites this paper
• HDAC8: A Promising Therapeutic Target for Acute Myeloid Leukemia

  2020cites this paper
• Safety, pharmacokinetics, and pharmacodynamics of panobinostat in children, adolescents, and young adults with relapsed acute myeloid leukemia

  2020cites this paper
• Location First: Targeting Acute Myeloid Leukemia Within Its Niche

  2020cites this paper
• Epigenetic therapies in acute myeloid leukemia: the role of hypomethylating agents, histone deacetylase inhibitors and the combination of hypomethylating agents with histone deacetylase inhibitors

  2020cites this paper
• HDAC Inhibitors in Acute Myeloid Leukemia

  2019cites this paper
• Epigenetic Therapies for Acute Myeloid Leukemia and Their Immune-Related Effects

  2019cites this paper
• Representation of therapy-related myelodysplastic syndrome in clinical trials over the past 20 years.

  2019cites this paper
• Safety and efficacy of oral panobinostat plus chemotherapy in patients aged 65 years or younger with high-risk acute myeloid leukemia.

  2019cites this paper
• Sorafenib plus intensive chemotherapy improves survival in patients with newly diagnosed, FLT3‐internal tandem duplication mutation–positive acute myeloid leukemia

  2019cites this paper
• Targeting the arginine metabolic brake enhances immunotherapy for leukaemia

  2019cites this paper
• Cotargeting the JAK/STAT signaling pathway and histone deacetylase by ruxolitinib and vorinostat elicits synergistic effects against myeloproliferative neoplasms

  2019cites this paper
• The histone deacetylase inhibitor Romidepsin induces as a cascade of differential gene expression and altered histone H3K9 marks in myeloid leukaemia cells

  2019cites this paper
• Histone Deacetylase Inhibition with Panobinostat Combined with Intensive Induction Chemotherapy in Older Patients with Acute Myeloid Leukemia: Phase I Study Results

  2019cites this paper
• Epigenetic therapy combinations in acute myeloid leukemia: what are the options?

  2019cites this paper
• Myeloid cell leukemia-1 dependence in acute myeloid leukemia: a novel approach to patient therapy

  2019cites this paper
• Clinical Trial Outcomes: What Matters to Patients.

  2019cites this paper
• Pharmacoepigenetics of Acute Myeloid Leukemia

  2019cites this paper
• Midostaurin: Nursing Perspectives on Managing Treatment and Adverse Events in Patients With FLT3 Mutation-Positive Acute Myeloid Leukemia and Advanced Systemic Mastocytosis.

  2019cites this paper
• Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 study.

  2019cites this paper
• A machine learning approach to integrate big data for precision medicine in acute myeloid leukemia

  2018cites this paper
• Advances in the drug therapies of acute myeloid leukemia (except acute wpromyelocytic leukemia)

  2018influential citation
• Megakaryocyte lineage development is controlled by modulation of protein acetylation

  2018cites this paper
• Reformulating acute myeloid leukemia: liposomal cytarabine and daunorubicin (CPX-351) as an emerging therapy for secondary AML

  2018cites this paper
• Possible reactivation of chromosomally integrated human herpesvirus 6 after treatment with histone deacetylase inhibitor.

  2018influential citation
• Panobinostat inhibits the proliferation of CD34+CD38−cells under stimulation of hematopoietic growth factors on AGM‐S3 cells in juvenile myelomonocytic leukemia

  2018cites this paper
• H2O2/Peroxynitrite-Activated Hydroxamic Acid HDAC Inhibitor Prodrugs Show Antileukemic Activities against AML Cells.

  2018cites this paper
• The high NRF2 expression confers chemotherapy resistance partly through up-regulated DUSP1 in myelodysplastic syndromes

  2018cites this paper
• Epigenetic Regulators in the Development, Maintenance, and Therapeutic Targeting of Acute Myeloid Leukemia

  2018cites this paper
• Approche Bayésienne de la survie dans les essais cliniques pour les cancers rares

  2018cites this paper
• Discovery Of Piperlongumine Derivatives As Anti-Leukemic And Anti-Prostate Cancer Agents

  2018cites this paper
• INI1 negative hepatoblastoma, a vanishing entity representing malignant rhabdoid tumor

  2018cites this paper
• Epigenetic drugs in overcoming the effects of bone marrow microenvironment-induced chemoprotection in pediatric AML

  2018cites this paper
• Tissue-Nonspecific Alkaline Phosphatase Is Required for MC3T3 Osteoblast–Mediated Protection of Acute Myeloid Leukemia Cells from Apoptosis

  2018cites this paper
• Advances in the drug therapies of acute myeloid leukemia (except acute promyelocytic leukemia)

  2018influential citation
• Role and regulation of microRNAs targeting BTK in acute myelogenous leukemia

  2018cites this paper
• Precision therapy for acute myeloid leukemia

  2018cites this paper
• Chromatin dynamics at the core of kidney fibrosis.

  2018cites this paper
• Phase I study of vorinostat in combination with isotretinoin in patients with refractory/recurrent neuroblastoma: A new approaches to Neuroblastoma Therapy (NANT) trial

  2018cites this paper
• Bayesian survival analysis in clinical trials: What methods are used in practice?

  2017cites this paper
• A randomized phase 2 study of idarubicin and cytarabine with clofarabine or fludarabine in patients with newly diagnosed acute myeloid leukemia

  2017cites this paper
• Selective Inhibitors of Histone Deacetylases 1 and 2 Synergize with Azacitidine in Acute Myeloid Leukemia

  2017cites this paper
• A novel regimen for relapsed/refractory adult acute myeloid leukemia using a KMT2A partial tandem duplication targeted therapy: results of phase 1 study NCI 8485

  2017cites this paper
• Integrated analysis of the molecular action of Vorinostat identifies epi-sensitised targets for combination therapy

  2017cites this paper
• Emerging therapies for acute myeloid leukemia

  2017cites this paper
• Molecular targeting in acute myeloid leukemia

  2017cites this paper
• Histone deacetylase inhibitors reduce differentiating osteoblast-mediated protection of acute myeloid leukemia cells from cytarabine

  2017cites this paper
• Histone Deacetylase Inhibitors as Anticancer Drugs

  2017cites this paper
• The prognostic significance of rapid peripheral blood blast clearance during the initial course of induction chemotherapy in young patients with de novo acute myeloid leukemia

  2017cites this paper
• Clinical Applications of Histone Deacetylase Inhibitors

  2017cites this paper
• Investigating the mechanisms by which histone deacetylase inhibitors induce apoptosis in cancer cells

  2017cites this paper
• Targeted Differentiation Therapy with Mutant IDH Inhibitors: Early Experiences and Parallels with Other Differentiation Agents

  2017cites this paper
• Peripheral blood blast clearance is an independent prognostic factor for survival and response to acute myeloid leukemia induction chemotherapy

  2016cites this paper
• HDACi-induced DNA damage: identifying potential endpoints for safety assessment

  2016cites this paper
• Histone deacetylases 1 and 2 cooperate in regulating BRCA1, CHK1, and RAD51 expression in acute myeloid leukemia cells

  2016cites this paper
• Epigenetic therapies by targeting aberrant histone methylome in AML: molecular mechanisms, current preclinical and clinical development

  2016cites this paper
• Revisiting maintenance therapy in acute myeloid leukemia with novel agents

  2016cites this paper
• Potential Therapeutic Approaches for the Treatment of Acute Myeloid Leukemia with AML1-ETO Translocation.

  2016cites this paper
• Histone Deacetylase Inhibitors: Updated Studies in Various Epigenetic-Related Diseases

  2016cites this paper
• Efficacy of Combined Epigenetic Therapies

  2016cites this paper
• Epigenetics in Acute Myeloid Leukemia

  2016cites this paper
• Mouse models for pre-clinical drug testing in leukemia

  2016cites this paper
• Novel immunotherapeutic approaches for the treatment of acute leukemia (myeloid and lymphoblastic)

  2016cites this paper
• Phase I study of the aurora A kinase inhibitor alisertib with induction chemotherapy in patients with acute myeloid leukemia

  2016influential citation
• DNA Methylation and Chromatin Remodeling: The Blueprint of Cancer Epigenetics

  2016cites this paper
• Epigenetics and approaches to targeted epigenetic therapy in acute myeloid leukemia.

  2016cites this paper
• c-Myc Modulation and Acetylation Is a Key HDAC Inhibitor Target in Cancer

  2016cites this paper
• Cardiovascular effects of histone deacetylase inhibitors epigenetic therapies: Systematic review of 62 studies and new hypotheses for future research.

  2016cites this paper